Welcome to our dedicated page for Windtree Therapeutics news (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on Windtree Therapeutics stock.
Windtree Therapeutics, Inc. (WINT) reports developments tied to its transition from a biotechnology-focused company toward a diversified, revenue-generating operating model. Company news has covered material agreements involving cardiovascular drug candidates, licensing activity for acute pulmonary treatments, patent estate updates for istaroxime and SERCA2a activators, and clinical or regulatory disclosures related to heart failure and surfactant-based programs.
Recurring updates also include stockholder approvals, governance matters, capital actions, OTC trading status, and operating and financial results. Windtree’s disclosed product and license references include SURFAXIN®, lyophilized lucinactant, and AEROSURF®, a drug-device combination based on aerosolized KL4 surfactant delivery.
Windtree Therapeutics, Inc. (WINT) announced positive topline results from its Phase 2 SEISMiC study of istaroxime for early cardiogenic shock, showing significant improvement in systolic blood pressure compared to controls. The results will be presented at the ESC Heart Failure Conference on May 23, 2022. For Q1 2022, the company reported an operating loss of $8.3 million and a net loss of $8.1 million ($0.29 per share), an improvement from $9.0 million in Q1 2021. Cash and cash equivalents stand at $15.5 million, providing a runway into Q1 2023.
Windtree Therapeutics announced a late-breaker presentation at the European Society of Cardiology Heart Failure Conference on May 22, 2022, detailing the efficacy of Istaroxime for pre-cardiogenic shock. The Phase 2 SEISMiC study showed that patients receiving Istaroxime significantly improved systolic blood pressure compared to controls. Cardiogenic shock, with a significant global market value of $1.25 billion, underscores the need for effective treatments. A conference call will follow the presentation to discuss additional study data.
Windtree Therapeutics announced positive results from the SEISMiC Phase 2 study of istaroxime in treating early cardiogenic shock. The trial, involving 60 patients, demonstrated significant improvements in systolic blood pressure (SBP) compared to placebo. This study is pivotal as it addresses a critical need in cardiogenic shock management, which currently lacks effective pharmacological options. The results will be further detailed at the European Society of Cardiology Heart Failure meeting scheduled for May 21-24, 2022, highlighting the potential for istaroxime as a first-in-class treatment.
Windtree Therapeutics to Present at Lytham Partners Conference
Windtree Therapeutics, Inc. (NASDAQ: WINT) announced that its CEO Craig Fraser will present at the Lytham Partners Spring 2022 Investor Conference on April 4, 2022, at 11:00 AM. The conference will be held virtually from April 4-7, 2022. Interested parties can click HERE for the live webcast. The company focuses on developing late-stage interventions for acute cardiovascular and pulmonary disorders, including its lead candidate, istaroxime, for acute heart failure.
Windtree Therapeutics (WINT) reported its fourth-quarter and full-year 2021 financial results, highlighting significant progress in clinical trials, particularly the completion of enrollment in the istaroxime phase 2 study for early cardiogenic shock. The company faced a net loss of $13.1 million in Q4 2021, up from $7.5 million in Q4 2020, and a full-year net loss of $67.6 million, compared to $32.6 million a year prior. Cash resources were $22.3 million as of December 31, 2021, expected to last into Q1 2023, supporting ongoing clinical development and patent protections into 2039.
Windtree Therapeutics announced positive results from its Phase 2 study of lucinactant (KL4 surfactant) for treating critically ill patients with severe COVID-19 associated acute respiratory distress syndrome (ARDS). The trial demonstrated that lucinactant was generally safe and well tolerated for intratracheal administration. Key findings included easier administration compared to previous formulations, stable or improved oxygenation in patients, and support for further development of this treatment approach, indicating potential for addressing ARDS from COVID-19 and other causes.
Windtree Therapeutics (NasdaqCM: WINT) has completed enrollment for its phase 2 study of istaroxime targeting early cardiogenic shock due to heart failure. The randomized, double-blind, placebo-controlled trial enrolled 60 patients, with 30 receiving istaroxime. Primary outcomes focus on systolic blood pressure (SBP) over 6 hours, with topline data expected in April 2022. Cardiogenic shock represents a critical need for new treatments, as current options have severe side effects. With a potential market value of $1.25 billion, istaroxime may address a significant gap in therapy.
Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that CEO Craig Fraser will present a corporate overview at the Oppenheimer 32nd Annual Healthcare Conference on March 15 at 1:20 p.m. ET. The presentation aims to highlight Windtree's advancements in treatments for acute cardiovascular and pulmonary disorders, primarily focusing on their lead candidate, istaroxime, for acute heart failure. Investors can view the live webcast and subsequent replay on the company's investor page.
Windtree Therapeutics (WINT) has completed enrollment in its Phase 2 study of lucinactant for COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS). The trial involves 20 patients and aims to assess the safety and tolerability of lucinactant delivered via an endotracheal tube. Results are expected in Q1 2022. Lucinactant, designed to mimic human surfactant, may alleviate surfactant deficiency caused by COVID-19, potentially improving lung function. The company is also developing treatments for acute cardiovascular conditions.
Windtree Therapeutics announced the issuance of U.S. Patent No. 11197869, covering the intravenous delivery of istaroxime for treating acute heart failure, protecting its intellectual property until late 2039. This patent allows for longer infusion durations, enhancing outcomes related to diastolic function. Istaroxime, a dual mechanism therapy, has shown significant improvements in cardiac function and has received FDA Fast Track designation. Windtree plans to expand its intellectual property around istaroxime as it approaches crucial clinical study results in 2022.